Alivus Life Sciences Ltd. Share Price

Alivus Life Sciences Acquires 9.21% Stake

Alivus Life Sciences Acquires 76% Stake in IQGEN-X Pharma

Key Highlights Alivus Life Sciences has received Board approval to acquire a 76% stake in IQGEN-X Pharma for approximately ₹9.12 Crore in cash. The acquisition is aimed at strengthening Alivus' capabilities across formulation development and its API & CDMO segments. Transaction Details • Stake Acquired: 76% of IQGEN-X Pharma's paid-up equity capital. • Consideration: Approximately ₹9.12 Crore, payable in cash. • The transaction involves 8,60,589 equity shares. • IQGEN-X Pharma develops formulations across Oral Solids, Sterile Injectables and Ophthalmic solutions. • FY26 Turnover: ₹3.48 Crore vs ₹3.18 Crore in FY25 and ₹2.68 Crore in FY24. • The transaction is at arm's length, with no related-party or promoter interest. What It Means • The acquisition expands Alivus Life Sciences' formulation development capabilities. • Access to Oral Solids, Sterile Injectables and Ophthalmic solutions can complement its existing API and CDMO capabilities. • The transaction supports Alivus' strategy of offering end-to-end solutions across the pharmaceutical value chain. • IQGEN-X Pharma has reported consistent turnover growth over the past three financial years. Market Impact Impact: Neutral to Positive The acquisition strengthens Alivus Life Sciences' capabilities across formulation development and could support its end-to-end API and CDMO offering. However, the acquired company's FY26 turnover of ₹3.48 Crore indicates that the immediate financial contribution is relatively limited based on the information provided. Learning Outcome An acquisition allows a company to obtain an existing business, its capabilities, technology, customers or expertise rather than developing them internally. Investors should assess both the strategic fit and the financial contribution of the acquired company when evaluating such transactions.

Alivus Life Sciences benefits from strong management efficiency, reflected in a return on equity (ROE) exceeding 19%, which is a key indicator of effective capital utilisation. The company’s net-debt-free status further enhances its financial stability, reducing risk and providing flexibility for future growth initiatives. Valuation metrics also support the stock’s appeal; with a price-to-book value around 4.5, it trades at a fair level relative to its historical peer group averages. Profit growth has been robust, with earnings rising by over 25% in the past year, outstripping the stock’s 21% return during the same period. The price-to-earnings-to-growth (PEG) ratio stands below 1, suggesting that the stock is reasonably valued given its earnings momentum. Promoter holdings remain substantial, signalling confidence from the company’s principal shareholders. Moreover, the stock has consistently outperformed the BSE500 index over the last three annual periods, underscoring its resilience and steady returns.

Alivus Life Sciences’ strong quarterly results reported for the period ending December 2025. The company posted its highest-ever quarterly net sales of ₹672.89 crores, alongside a record PBDIT of ₹231.28 crores. The operating profit margin relative to net sales also reached a peak of 34.37%, signalling efficient cost management and robust profitability. These figures highlight the company’s operational strength and ability to generate healthy earnings growth. Management efficiency is another key factor supporting investor optimism. Alivus boasts a high return on equity (ROE) of 18.73%, reflecting effective utilisation of shareholder capital. The company is also net-debt free, which reduces financial risk and enhances balance sheet stability. Despite trading at a premium price-to-book value of 4.5, the valuation appears justified given the company’s strong profitability and growth metrics. Over the past year, while the stock’s price appreciation was relatively modest at 1.92%, the company’s profits have increased by 27.5%. This divergence suggests that earnings growth is outpacing share price gains, potentially indicating undervaluation or room for further price appreciation. The PEG ratio of 0.9 further supports this view, implying that the stock’s price growth is reasonable relative to its earnings growth

🚀 Trendline Breakout Brewing in a Fundamentally Strong Pharma Stock